Diabetes & Your Kidneys — A Message of Care and Action

The situation in India

• Over 50% of people with diabetes in India are estimated to be undiagnosed. Early detection matters.
• Diabetic kidney disease is common. ~30–34% of people with type 2 diabetes have signs of DKD. This means about 1 in 3 clinic patients with diabetes may already have early kidney involvement.
• Loss to follow-up is a big problem. Many patients stop regular care because of travel, cost, or confusion — studies in India show important delays and missed appointments for diabetes complications (for example diabetic eye clinics), contributing to late diagnosis and worse outcomes.

Typical pattern for an Indian patient who develops DKD

• Often silent at first: small amounts of protein (albumin) in urine (microalbuminuria) or mild fall in eGFR without symptoms.
• Hypertension (BP >140/90 mm Hg) and high triglycerides (>128 mg/dl) commonly coexist and accelerate damage.
• Many present late — with reduced eGFR, significant proteinuria, fatigue, swelling or complications — because screening or follow-up was missed.

How kidney disease links to heart and eyes

• Cardiovascular risk: DKD is a powerful marker of increased heart-attack, stroke and heart-failure risk. Even mild albuminuria or small eGFR falls raise cardiovascular risk.
• Eyes: Microvascular damage tends to run together — retinopathy commonly coexists with nephropathy. People who skip follow-up for eye checks often also miss kidney screening. Regular screening catches both early.

Who is at higher risk of developing DKD?

• Longer diabetes duration (>7 years).
• Poor blood-sugar control (HbA1c >7).
• High blood pressure (BP >140/90 mm Hg is the single most important modifiable risk in many studies).
• Albuminuria (even small amounts >20).
• Older age, smoking, high triglycerides and central/visceral obesity.
• Family history of kidney disease.

How to define DKD and spot progression

• Early signs: urine albumin-to-creatinine ratio (ACR) showing microalbuminuria (>30 mg/gm on 1st or 2nd urine sample, or random sample showing ACR >20) &/or eGFR 60–90 with albuminuria = early disease.
• Monitoring: check eGFR and urine ACR routinely as guided by your physician.
• Rapid progressors: KDIGO/experts define rapid decline as an eGFR fall of ≥5 mL/min/1.73 m² per year — these patients need urgent action.

Blood-pressure goals for people with diabetes + kidney risk

• For most people with diabetes and CKD, professional guidance recommends a target of <130/80 mmHg if it can be safely achieved; some CKD guidance suggests considering an even lower standardized systolic target (e.g., <120 mmHg) in selected patients if tolerated and under close supervision. Targets must be individualized.

How to slow progression — practical steps for patients

1. Get screened now — ask your doctor for urine ACR and eGFR (at diagnosis and at least annually). Early detection is simple and cheap.
2. Blood pressure control — aim for targets your doctor sets (often <130/80 mmHg); take BP medicines regularly.
3. Start or continue RAAS blocker if albuminuria or hypertension is present, unless contraindicated. This protects kidneys and heart along with BP optimisation.
4. Ask about SGLT2 inhibitors — they slow kidney decline and reduce heart failure; many patients with T2D + CKD benefit.
5. Ask about GLP-1 analogues: Semaglutide, Tirzepatide.
6. Control blood sugar to individualized HbA1c goals (KDIGO suggests an individualized range, commonly ~<7% unless risks of hypoglycaemia).
7. Reduce salt, control weight, increase activity, stop tobacco. Small changes add up.
8. Avoid harmful medicines/NSAIDs when possible and tell every doctor you have CKD — some drugs need dose changes.
9. Keep follow-ups — missed appointments are the single biggest reason kidney disease is diagnosed late. If travel/cost is a problem, ask your clinic about community services or local testing.

Our research in this area

Peer-reviewed publications and conference presentations by Dr. Vishal Gupta and colleagues.

1. Vishal Gupta. Comparison of the effect of up-titration of angiotensin receptor blocker (ARB) alone vs ARB plus finerenone on renal markers in type 2 diabetes with stage 1-3 nephropathy receiving SGLT2i therapy. Short Oral Station 20, SODA Area on Level 2 1150, 62nd EASD Annual Meeting, Milan, 29 September 2026.
2. Vishal Gupta. 403-P: Evaluating the Effect of Finerenone on Renal Markers in Patients with Diabetic Nephropathy (Stage 1–3) Receiving Angiotensin Receptor Blockers and SGLT2i Therapy. Diabetes 20 June 2025;74(Supplement_1):403–P. doi:10.2337/db25-403-P
3. Gupta V. Comparison of effects of canagliflozin, dapagliflozin and empagliflozin on cardio-renal biomarkers in 150 patients with type 2 diabetes. 58th EASD Annual Meeting, short oral presentation 866; Sept 2022. (Conference resource: EASD media centre).
4. Gupta V, et al. Canagliflozin may offer vascular and renal protection in patients with type 2 diabetes mellitus — an Indian perspective. Indian J Cardiol (Photon) 2019;112:145–165.
5. Gupta V, et al. Comparison of cardiovascular (NT-proBNP) and renal biomarkers in 280 T2DM patients with microalbuminuria vs. normoalbuminuria. Diabetes 2019;68:2229-PUB. doi:10.2337/db19-2229-PUB
6. Gupta V, Teli V. Subgroup analysis to evaluate effects of baseline characteristics on markers of renal and cardiovascular risk in type 2 diabetes patients treated with SGLT2 inhibitor (canagliflozin). Abstract P2418-PUB. American Diabetes Association 2017, San Diego, USA.
7. Teli V, Gupta V. A real-life prospective study to evaluate effect of sodium-glucose co-transporter-2 inhibitor (canagliflozin) therapy on cardiovascular and renal markers in patients with type 2 diabetes mellitus. Poster P1204. American Diabetes Association 2017, San Diego, USA.